- New patient and physician surveys reveal differing perspectives on disease burden, treatment goals, and long-term management - WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced The Distance Between platform and new findings from Zenas-sponsored patient and healthcare professional (HC
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentation at the Jefferies London Global Healthcare Conference on Monday, November 16, 2026, at 5:00 p.m. GMT. A live webcast and archived repl
WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announced that it will present seven posters at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026) taking place October 21-23, 2026, in Toronto, Canada. The Company will also host a Symposium featuring a panel of Multiple Sclerosis (MS) exper
Zenas BioPharma is advancing obexelimab for IgG4-RD, with FDA acceptance and a May 2027 PDUFA date. Read why ZBIO stock is a Buy.
Zenas BioPharma (NasdaqGS:ZBIO) filed shelf registrations totaling more than US$240 million, according to recent regulatory disclosures. The filings include a broad shelf registration for potential future securities offerings across multiple instruments. A separate portion of the shelf is earmarked for an employee stock ownership plan related offering. The new shelf registrations and ESOP related shelf tell only part of the Zenas BioPharma story for investors to weigh. Our analysis turns up...
WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET. Zenas’ management team will be join
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ETMor
This is the newest page. Registered accounts read further back.